of patients with DED have excessive tear evaporation associated with meibomian gland dysfunction (MGD)3-5
DED is a multifactorial
clinical challenge2
Clinic-based cohort studies have shown
I wish my eye doctor spent more time explaining what causes dry eye.
*Survey sponsored by Bausch + Lomb was conducted by The Harris Poll amongst N = 732 US “dry eye sufferers” (those who often/always experience eye dryness and/or have been diagnosed with DED). Among total dry eye sufferers, 71% somewhat or strongly agreed with the statement "I wish my eye doctor spent more time explaining what causes dry eye.”6
The main contributor to excessive tear evaporation is MGD,7 which is characterized by:
Changes in meibum composition7
Reduced meibum secretion7
Breakdown of the tear film lipid layer2,7
Reduced blink rate, increased screen time, and lid laxity
can also lead to increased tear evaporation.7,8
Excessive tear evaporation triggers a vicious cycle1,2
†Desiccation is the drying of the ocular surface due to tear evaporation exceeding tear production.
The continuation of this cycle can contribute to the loss of ocular surface homeostasis that can exacerbate DED symptoms9
In a survey of more than 1000 ECPs10:
reported an increase in patients aged 18-34 presenting DED symptoms
indicated that the use of technology contributes to DED symptoms
agreed that DED is becoming more common due to a multiscreen lifestyle
Learn more from the TFOS Lifestyle Epidemic Report about the impact of today’s world on DED
TFOS, Tear Film & Ocular Surface Society.
“
Successful treatment of dry eye should be aimed at restoring the homeostasis of the ocular surface microenvironment.”
—American Academy of Ophthalmology Dry Eye Syndrome Preferred Practice Pattern® guidelines11
Not all prescription eye drops for DED are the same12-17
Most leave excessive evaporation unaddressed—as a result, appropriate management of evaporative DED may require an Rx option that directly targets tear evaporation12-18
‡Survey sponsored by Bausch + Lomb was conducted by The Harris Poll amongst N = 732 US “dry eye sufferers” (those who often/always experience eye dryness and/or have been diagnosed with DED).6
Watch this recommended video about DED
Understanding Dry Eye Disease and Diagnosis With Dr. Marc Bloomenstein and Patient Rahnee
UP NEXT
About
MIEBO
INDICATION
MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.
IMPORTANT SAFETY INFORMATION
- MIEBO is contraindicated in patients with known hypersensitivity to perfluorohexyloctane
- MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
- Instruct patients to instill one drop of MIEBO into each eye four times daily
- The safety and efficacy in pediatric patients below the age of 18 have not been established
- In pivotal trials, the most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)
Click here for full Prescribing Information for MIEBO.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
References: 1. Sheppard JD, Nichols KK. Dry eye disease associated with meibomian gland dysfunction: focus on tear film characteristics and the therapeutic landscape. Ophthalmol Ther. 2023;12(3):1397-1418. doi:10.1007/s40123-023-00669-1 2. Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15(4):802-812. doi:10.1016/j.jtos.2017.08.003 3. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31(5):472-478. doi:10.1097/ICO.0b013e318225415a 4. Rabensteiner DF, Aminfar H, Boldin I, et al. The prevalence of meibomian gland dysfunction, tear film and ocular surface parameters in an Austrian dry eye clinic population. Acta Ophthalmol. 2018;96:e707-e711. doi:10.1111/aos.13732 5. Badian RA, Utheim TP, Chen X, et al. Meibomian gland dysfunction is highly prevalent among first-time visitors at a Norwegian dry eye specialist clinic. Sci Rep. 2021;11(23412):1-8. doi:10.1038/s41598-021-02738-6 6. Bausch + Lomb 2025 State of Dry Eye Survey. 7. Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438-510. doi:10.1016/j.jtos.2017.05.011 8. Al-Mohtaseb Z, Schachter S, Shen Lee B, Garlich J, Trattler W. The relationship between dry eye disease and digital screen use. Clin Ophthalmol. 2021;15:3811-3820. doi:10.2147/OPTH.S321591 9. Zhang R, Pandzic E, Park M, Wakefield D, Di Girolamo N. Inducing dry eye disease using a custom engineered desiccation system: impact on the ocular surface including keratin-14-positive limbal epithelial stem cells. Ocul Surf. 2021;21:145-159. doi:10.1016/j.jtos.2021.04.006 10. Modern technology and a multi-screen lifestyle viewed as important factors in rising prevalence of dry eye disease. PR Newswire. Published October 17, 2016. Accessed September 8, 2025. https://www.prnewswire.com/news-releases/modern-technology-and-a-multi-screen-lifestyle-viewed-as-important-factors-in-rising-prevalence-of-dry-eye-disease-597289311.html 11. Amescua G, Ahmad S, Cheung AY, et al; American Academy of Ophthalmology Preferred Practice Pattern Cornea/External Disease Panel. Dry Eye Syndrome Preferred Practice Pattern®. Ophthalmology. 2024;131(4):PP1-P49. doi:10.1016/j.ophtha.2023.12.041 12. Cequa. Prescribing Information. Sun Pharmaceutical Industries, Inc. 13. Eysuvis. Prescribing Information. Alcon Laboratories, Inc. 14. Restasis. Prescribing Information. AbbVie Inc. 15. Tyrvaya. Prescribing Information. Oyster Point Pharma, Inc. 16. Vevye. Prescribing Information. Harrow Eye, LLC. 17. Tryptyr. Prescribing Information. Alcon Laboratories, Inc. 18. MIEBO. Prescribing Information. Bausch & Lomb, Inc.
You are now leaving MIEBO-ECP.COM
You are now leaving the MIEBO ECP website and are going to a website that Bausch + Lomb does not operate and to which Bausch + Lomb’s Privacy Policy does not apply.
Bausch + Lomb is not responsible for the content, format, maintenance, or policies of the website you are about to visit and does not endorse or monitor any content on such website.
INDICATION AND IMPORTANT
SAFETY INFORMATION
INDICATION
MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.
IMPORTANT SAFETY INFORMATION
- MIEBO is contraindicated in patients with known hypersensitivity to perfluorohexyloctane
- MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
- Instruct patients to instill one drop of MIEBO into each eye four times daily
- The safety and efficacy in pediatric patients below the age of 18 have not been established
- In pivotal trials, the most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)
Click here for full Prescribing Information for MIEBO.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
FAQs